피부과용 의약품 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global dermatologicals market size is expected to reach USD 76.05 Billion in 2034 from USD 29.61 Billion in 2025, growing at a CAGR of 11.05% during 2026-2034.This market is growing as demand for treatments addressing skin diseases and related conditions continues across healthcare settings. Dermatological products include prescription medicines, topical treatments, and other therapeutic formulations used for conditions such as acne, eczema, psoriasis, fungal infections, and inflammatory skin disorders. Increasing awareness of skin health, improved access to dermatology consultations, and greater recognition of chronic skin conditions are supporting demand. Consumers and healthcare professionals are also paying more attention to the impact of skin disorders on comfort, daily activities, and quality of life, encouraging continued investment in effective treatment options.

Market growth is driven by advances in dermatology research, the development of targeted therapies, and expanding availability of topical and systemic treatments. Pharmaceutical companies are investigating new medicines for inflammatory and autoimmune skin disorders, including biologic therapies and other treatments that target specific disease pathways. Improvements in formulation technologies are helping manufacturers develop products with different delivery characteristics and patient-use requirements. Generic medicines also contribute to treatment availability across price-sensitive markets. Furthermore, teledermatology and digital consultation services are helping some patients access specialist guidance, potentially supporting earlier evaluation and better continuity of care.

The future prospects of this market will depend on continued pharmaceutical innovation, improved disease management, and the development of more personalized treatment approaches. Advances in biologics, topical drug delivery, and targeted medicines may expand options for patients with chronic or difficult-to-treat conditions. Digital dermatology tools and AI-assisted image analysis could support clinical assessment and follow-up when appropriately validated. Growing interest in treatment adherence and patient-centered care may also encourage the development of convenient formulations. However, treatment costs, adverse effects, regulatory requirements, and differences in access to dermatology services will influence market development. Continued research and responsible treatment practices will remain important for sustained growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease

• Acne
• Dermatitis
• Psoriasis
• Skin Cancer
• Rosacea
• Alopecia
• Others

By Type

• Prescription-based drugs
• Over-the-counter drugs

By Route of Administration

• Topical Administration
• Oral Administration
• Parenteral Administration

COMPANIES PROFILED

• AbbVie, Galderma, Johnson & Johnson, L'Oreal, Sanofi, Novartis, Eli Lilly, Bristol Myers Squibb, Amgen, UCB, Sun Pharma, Teva Pharmaceuticals, Bausch Health, Almirall, LEO Pharma, Regeneron, Incyte, Arcutis Biotherapeutics, Pfizer, Bayer

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DERMATOLOGICALS MARKET: BY DISEASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease
• 4.2. Acne Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dermatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Psoriasis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Skin Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Rosacea Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Alopecia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DERMATOLOGICALS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prescription-based drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Over-the-counter drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DERMATOLOGICALS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Topical Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Parenteral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DERMATOLOGICALS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Disease
  • 7.2.2 By Type
  • 7.2.3 By Route Of Administration
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Disease
  • 7.3.2 By Type
  • 7.3.3 By Route Of Administration
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Disease
  • 7.4.2 By Type
  • 7.4.3 By Route Of Administration
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Disease
  • 7.5.2 By Type
  • 7.5.3 By Route Of Administration
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Disease
  • 7.6.2 By Type
  • 7.6.3 By Route Of Administration
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DERMATOLOGICALS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie
  • 9.2.2 Galderma
  • 9.2.3 Johnson & Johnson
  • 9.2.4 L'Oreal
  • 9.2.5 Sanofi
  • 9.2.6 Novartis
  • 9.2.7 Eli Lilly
  • 9.2.8 Bristol Myers Squibb
  • 9.2.9 Amgen
  • 9.2.10 UCB
  • 9.2.11 Sun Pharma
  • 9.2.12 Teva Pharmaceuticals
  • 9.2.13 Bausch Health
  • 9.2.14 Almirall
  • 9.2.15 LEO Pharma
  • 9.2.16 Regeneron
  • 9.2.17 Incyte
  • 9.2.18 Arcutis Biotherapeutics
  • 9.2.19 Pfizer
  • 9.2.20 Bayer